Gilead to present liver disease data at EASL conference By Investing.com

Gilead Sciences will present 29 abstracts at the EASL Congress in May 2026, highlighting additional clinical data for Livdelzi in primary biliary cholangitis, bulevirtide for HDV, and hepatitis B/C research. The company also reported Q1 2026 non-GAAP EPS of $2.03 versus $1.90 expected and revenue of $7.0 billion versus $6.91 billion, then raised 2026 revenue guidance by $400 million. Analysts remained mixed, with Morgan Stanley cutting its target to $168 from $175 and RBC reiterating Sector Perform with a $122 target.

Analysis

GILD is increasingly behaving like a self-funded pipeline platform rather than a single-product story, which matters because the market is willing to pay a higher multiple when earnings can continuously recycle into late-stage optionality. The near-term upside is not from any one abstract; it is from the accumulation effect: each additional dataset reduces perceived binary risk around liver franchises and strengthens the case that the company can defend cash flow while extending growth into the late 2020s.

The second-order beneficiary is not just GILD’s equity; it is the broader hepatology ecosystem, where positive readthrough can compress the implied risk premium on adjacent names with liver-disease exposure and validate the category for payers. If the liver stiffness and biomarker work continues to show durability, the market may start assigning more value to earlier-line positioning and longer duration treatment, which is structurally better for revenue quality than one-time uptake spikes.

The key risk is that investors are extrapolating biomarker success into clinical and commercial durability too quickly. In PBC and HDV, the gap between surrogate improvement and hard outcomes can stay unresolved for years, so any disappointment in safety, adherence, or payer willingness to reimburse combination/earlier-use therapy could cap the rerating. That makes this more of a months-to-years catalyst stack than a days-to-weeks trading event, with the main reversal trigger being data that looks statistically clean but commercially non-incremental.

Consensus may be underestimating how much of GILD’s current valuation support comes from capital return plus pipeline credibility, not just the legacy virology franchise. That is important because if the liver program keeps de-risking, downside becomes more asymmetric to the upside than the headline multiple suggests. Conversely, if the congress data are merely confirmatory, the stock can drift rather than re-rate, because the market has already priced in a decent amount of execution quality.

Key Decisions for Investors

• Long GILD into the congress window, with a 4-8 week horizon, targeting a modest multiple rerating if liver data reinforce durability; use a 3-5% stop if the abstracts fail to improve confidence on progression-risk subgroups.
• Buy GILD Jan-2027 call spreads to express upside from pipeline de-risking while limiting premium bleed; best risk/reward if implied volatility stays anchored ahead of the meeting.
• Pair long GILD / short a lower-quality hepatology or single-asset biotech basket over 1-3 months, betting that credible multi-asset cash generation gets rewarded more than speculative liver readouts.
• If the congress data are strong but the stock gaps up, fade part of the move with covered calls against existing GILD longs; the market may have already discounted a large share of the near-term catalyst.